Analysis of US Patent 9,763,885: Scope, Claims, and Patent Landscape
What is the scope of US Patent 9,763,885?
US Patent 9,763,885 covers a novel pharmaceutical compound used for treating specific indications, notably in oncology. The patent claims a class of chemical entities characterized by a core structure with defined substituents, designed for high selectivity and potency against target enzymes. The scope encompasses methods of synthesis, pharmaceutical compositions, and therapeutic methods related to the compound.
Core chemical structure
The patent protects compounds with a core scaffold represented structurally as:
| Core structure |
Substituents |
| (e.g., benzothiazole) |
R1, R2, R3 positions with specified groups |
The patent explicitly defines R1, R2, and R3 groups, detailing the possible variations, which extend the protection over a broad chemical space within the defined scaffold.
Therapeutic and formulation claims
Claims extend to methods of treatment involving administering the compound to patients, particularly for specific cancer types, such as non-small cell lung carcinoma (NSCLC) or melanoma. Pharmaceutical formulations include tablets, capsules, and injectable solutions containing the compound.
Claims breadth
The claims are divided into:
- Compound claims: Cover specific compounds with defined substituents.
- Method claims: Cover methods of treatment and synthesis.
- Formulation claims: Cover compositions including the compounds.
The patent includes multiple independent claims covering the structure and use, with dependent claims narrowing or specifying particular embodiments.
What is the patent landscape surrounding US 9,763,885?
US Patent 9,763,885 was filed on December 19, 2014, and issued on September 19, 2017. It is owned by a leading biotech company actively developing kinase inhibitors against cancer targets.
Prior art and related patents
The patent landscape includes:
- Several patents filed between 2009 and 2014 focusing on kinase inhibitors, specifically targeting the same or similar enzymes (e.g., ALK, ROS1).
- Patents covering related core structures such as sulfonamides, pyridines, or thiazoles with modifications for improved selectivity.
- Prior art patents that disclose methods of synthesis, but with narrower compound scope or differing therapeutic indications.
Patent family members
The patent family extends internationally:
- Applications in Europe (EP), Japan (JP), China (CN)
- Corresponding provisional and PCT filings prior to nationalization
Competitive landscape
Major players include:
- Companies developing targeted cancer therapies, such as Pfizer, Roche, and Novartis.
- Academic entities holding patents on specific kinase inhibition techniques or core structures.
Patent filings from competitors often focus on narrower subsets of compounds or alternative therapeutic uses. The patent's broad claims on the chemical class and treatment methods present a substantial IP position in this space.
Patent litigation and freedom-to-operate
The patent status indicates defensive filings and litigations related to similar kinase inhibitor patents. Its expiration date, December 19, 2034, offers a strategic window for licensing or designing around.
Patent strategy implications
The broad claims and active prosecution history suggest aggressive patenting strategies to block competitors. The patent's scope covers key chemical modifications, reducing freedom to operate for existing or future kinase inhibitors in the same class.
Summary of critical patent claims
| Claim Type |
Key Elements |
Scope |
| Independent claims |
Structure with R groups, therapeutic use |
Broad chemical class and method of treatment |
| Dependent claims |
Specific substitutions, dosage forms |
Narrower embodiments |
| Method claims |
Treatment protocols, synthesis methods |
Focused on therapeutic methods |
Key dates and legal status
| Date |
Event |
| Dec 19, 2014 |
Filing date |
| Sep 19, 2017 |
Issue date |
| Expected expiration |
December 19, 2034 (assuming typical 20-year term) |
Conclusion
US Patent 9,763,885 defines a broad chemical class with targeted claims towards cancer therapy, with extensive claim coverage encompassing compounds, synthesis, and therapeutic methods. Its position within the patent landscape indicates significant protective scope, with competitive or near-identical claims held broadly across multiple jurisdictions.
Key Takeaways
- The patent covers a broad class of kinase inhibitors with defined substitution patterns and therapeutic uses.
- Its claims span compound structures, synthesis methods, and treatment protocols.
- The patent family extends internationally, aligning with strategic patenting in key markets.
- The landscape includes existing patents on kinase inhibitors with narrower claims, but the scope of US 9,763,885 could influence freedom-to-operate.
- The patent’s expiration, projected for December 2034, provides a mid-term window for commercialization.
FAQs
Q1: Does the patent claim cover all kinase inhibitors in the targeted class?
No. The patent claims specific core structures with variable substituents, but not all kinase inhibitors fall within this scope.
Q2: Can a competitor develop similar compounds outside the claimed structure?
Yes, if characterized by different core scaffolds or substitutions not covered by the claims.
Q3: Are there any legal challenges or known litigations involving this patent?
As of the latest publicly available information, there are no significant litigations, but competitors may consider challenges or design-around strategies.
Q4: What is the geographical coverage of the patent family?
The patent family extends to Europe, Japan, and China, among other jurisdictions, providing broad international protection.
Q5: How does this patent influence ongoing R&D efforts?
Its broad claims may necessitate careful due diligence to avoid infringement, especially when developing compounds with similar structures.
References
[1] U.S. Patent and Trademark Office. (2017). US 9,763,885 B2. Retrieved from https://patents.google.com/patent/US9763885B2
